Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma-Reference-Cited by-同舟云学术

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma

Published:2017-01-28 Issue:8 Volume:8 Page:14017-14028
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mondello Patrizia¹,Derenzini Enrico¹,Asgari Zahra¹,Philip John²,Brea Elliott J.³,Seshan Venkatraman⁴,Hendrickson Ronald C.²,de Stanchina Elisa⁵,Scheinberg David A.³,Younes Anas¹

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

5. Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies;Journal of Hematology & Oncology;2024-09-04

2. Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma;Leukemia;2024-07-19

3. MYC the oncogene from hell: Novel opportunities for cancer therapy;European Journal of Medicinal Chemistry;2024-03

4. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma;International Journal of Oncology;2023-12-08

5. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms;Cancer Chemotherapy and Pharmacology;2023-11-08